WORKSHOPS
WS-01
Clinical Impact and Laboratory Detection of Newer β-Lactamases
1:00 p.m. - 4:30 p.m.
Convener and Faculty:
Kenneth S. Thomson; Creighton University School of Medicine, Omaha, NE.
Description:
The focus will be on laboratory detection and clinical significance of ESBLs, AmpC β-lactamases, and carbapenemases and the issues and controversies these enzymes create. Issues addressed will include: Do I need to perform additional confirmatory tests? What interpretation provides the most accurate report – CLSI, FDA, or other? Is it necessary to edit or modify results? A variety of diagnostic methodologies and their limitations will be covered.
WS-02
Investigating Foodborne Illness Outbreaks: Who Does What?
1:00 p.m. - 4:30 p.m.
Convener:
John J. Guzewich; FDA, College Park, MD.
Faculty:
John J. Guzewich; FDA, College Park, MD.
Ian T. Williams; Centers for Disease Control, Atlanta, GA.
Sherri A. McGarry; FDA/CFSAN, College Park, MD.
Description:
Foodborne illness outbreaks can be linked to many different foods and involve investigations by many different government agencies. Using two high profile outbreak examples this workshop will illustrate the roles and responsibilities of state and federal public health and regulatory agencies as they worked together to solve the mysteries of two Salmonella outbreaks ultimately linked to peanut butter and shell eggs.
WS-03
Laboratory Operations During a Disaster: Are You Prepared?
1:00 p.m. - 4:30 p.m.
Conveners and Faculty:
Thomas Williams; Methodist Hospital, Omaha, NE.
Gina Potenza; Great Expressions Dental Centers, Rochester MI.
Description:
Emergency operations planning is foreign to laboratory professionals and healthcare, but is essential to promote our mission during disasters. This course will familiarize participants with the domestic structure and terminology of emergency planning, provide several potential scenarios which especially challenge laboratory disaster operations, and tour participants through the terms, tools, and steps used by professionals in EOP development and sustainment, following CLSI GP-36 (currently in development), for which the presenters serve as Chairholder and Vice Chairholder.
WS-04
Clinical Trials Microbiology: From Drug Discovery to Delivery
1:00 p.m. - 4:30 p.m.
Conveners:
Frank O. Wegerhoff; Covance Central Laboratory Services, Indianapolis, IN
Judith Steenbergen; Cubist Pharmaceuticals, MA
Faculty:
Gregory Stone; Antibacterials, Pfizer, Inc., Groton, CT
Judith Steenbergen; Cubist Pharmaceuticals, MA
Frank O. Wegerhoff; Covance Central Laboratory Services, Indianapolis, IN
Mary R. Motyl; Merck & Co. Inc., Rahway, NJ
Description:
On completion of this workshop, participants will understand the entire clinical trials process from initial drug discovery to final market delivery. The focus of the workshop will be on how new drug compounds are discovered, early development, phases of clinical trials, the role of contract research organizations (CRO's) and the FDA, laboratory testing, and data management.
WS-05
The Gram Stain: Making the Most of the Original Real-Time Multiplex Test
1:00 p.m. – 4:30 p.m.
Convener and Faculty:
Steven Dallas; University of Texas Health Science Center, San Antonio, TX
Description:
In this age of molecular microbiology, the Gram stain is still an amazingly useful real time multiplex test. It is fast, inexpensive, can visualize multiple pathogens, and in the hands of an experienced microbiologist it can have direct impact on patient care in just a few minutes. However, meaningful results depend on five keys: the right specimen, appropriate application of the specimen to the slide, good staining, correct interpretation, and clear reporting. Using pre-stained glass slides and digital images, the participants will examine real patient cases in the context of these five keys and how each one affects the Gram stain result and how these results can affect patient care in a positive or negative way. Second, the presenter will use real life examples of dialog with clinicians that help turn unknowns into known so that patients are treated effectively. Lastly, the presenter will address ways to avoid common Gram stain errors and craft an effective Gram stain QA and review policy.
